fluorouracil has been researched along with Cancer of Oropharnyx in 114 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hyperammonemia or hyperammonemic leukoencephalopathy sometimes occurs as an adverse event after 5-fluorouracil (5-FU) chemotherapy." | 7.74 | The aggravating factors of hyperammonemia related to 5-fluorouracil infusion--a report of two cases. ( Asakage, T; Kikuta, S; Kubota, A; Nakao, K; Sugasawa, M, 2008) |
| "Hyperammonemia or hyperammonemic leukoencephalopathy sometimes occurs as an adverse event after 5-fluorouracil (5-FU) chemotherapy." | 3.74 | The aggravating factors of hyperammonemia related to 5-fluorouracil infusion--a report of two cases. ( Asakage, T; Kikuta, S; Kubota, A; Nakao, K; Sugasawa, M, 2008) |
| "Nab-paclitaxel (A) is a novel albumin-bound paclitaxel with a superior therapeutic index to docetaxel." | 2.79 | Phase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the oropharynx. ( Bayley, A; Chan, K; Chen, EX; Chin, S; Diaz-Padilla, I; Hope, A; Hossain, M; Kim, J; Loong, HH; Palma, D; Razak, AR; Read, N; Siu, LL; Waldron, J; Wang, L; Winquist, E, 2014) |
| "0 Gy/fraction) in combination with weekly cetuximab throughout radiotherapy." | 2.76 | Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx--TPF-C-HIT. ( Debus, J; Desta, A; Habl, G; Jensen, AD; Krauss, J; Mavtratzas, A; Münter, MW; Potthoff, K; Windemuth-Kiesselbach, C, 2011) |
| "122 patients with primary squamous cell carcinoma of the lip, the oral cavity and the oropharynx have been treated with 100 mg/m2 cisplatin bolus infusion and 120-h continuous infusion of 1000 mg/m2 5-fluorouracil following radical surgery; 99 patients completed all 3 cycles." | 2.71 | Postoperative chemotherapy with cisplatin and 5-fluorouracil in cancer of the oral cavity and the oropharynx--long-term results. ( Bitter, K; Ghahremani, MT; Kovács, AF; Stefenelli, U, 2003) |
| "Patients with a squamous cell carcinoma of the oropharynx for whom curative radiotherapy or surgery was considered feasible were entered in a multicentric randomized trial comparing neoadjuvant chemotherapy followed by loco-regional treatment to the same loco-regional treatment without chemotherapy." | 2.69 | Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tête et du Cou (GETTEC). ( Coche-Dequeant, B; De Raucourt, D; Domenge, C; Hill, C; Lefebvre, JL; Luboinski, B; Marandas, P; Rhein, B; Sancho-Garnier, H; Stromboni-Luboinski, M; Wibault, P, 2000) |
| "To analyze clinical and pharmacokinetic data of cisplatin (CP)/fluorouracil (FU)/l folinic acid (l FA) chemotherapy administered as first-line treatment to locally advanced head and neck cancer patients." | 2.68 | Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. ( Dassonville, O; Demard, F; Etienne, MC; Guillot, T; Milano, G; Mobayen, H; Otto, J; Saudes, L; Schneider, M; Thyss, A, 1995) |
| "In head and neck squamous cell carcinoma (HNSCC), the inhibition of epidermal growth factor receptor (EGFR) signaling as a central step in carcinogenesis, progression, and metastasis is the predominant approach." | 2.49 | Molecular targeting agents in the context of primary chemoradiation strategies. ( Knecht, R; Laban, S; Münscher, A; Schafhausen, P; Tribius, S; Wang, CJ, 2013) |
| "Oropharyngeal and esophageal squamous cell carcinomas, especially the latter, are a lethal disease, featuring intratumoral cancer cell heterogeneity and therapy resistance." | 1.51 | Three-Dimensional Organoids Reveal Therapy Resistance of Esophageal and Oropharyngeal Squamous Cell Carcinoma Cells. ( Arigami, T; Avadhani, NG; Bass, AJ; Basu, D; Chandramouleeswaran, PM; Diehl, JA; Doki, Y; Ginsberg, GG; Giroux, V; Hara, T; Kasagi, Y; Kijima, T; Kikuchi, O; Kita, Y; Klein-Szanto, AJ; Mori, M; Muir, AB; Muto, M; Naganuma, S; Nakagawa, H; Natsugoe, S; Ohashi, S; Omoto, I; Rustgi, AK; Sahu, V; Sasaki, K; Shimonosono, M; Shinden, Y; Tanaka, K; Uchikado, Y; Whelan, KA, 2019) |
| "Distant metastases (DM) are a leading cause of death for patients with oropharyngeal cancer (OPSCC)." | 1.51 | The addition of chemotherapy to radiotherapy did not reduce the rate of distant metastases in low-risk HPV-related oropharyngeal cancer in a real-world setting. ( Griffiths, RJ; Hall, SF; Liu, FF; O'Sullivan, B, 2019) |
| "Advanced stage squamous cell carcinoma of the head and neck carries an overall poor prognosis, and survivorship gains have remained relatively stagnant compared to other malignancies due to its complex tumor biology and lack of proven effective targeting agents." | 1.46 | Personalized Medicine Approach for an Exceptional Response to Multiple-recurrent and Metastatic HER2-positive Oropharyngeal Squamous Cell Carcinoma. ( Bhandari, M; Jones, RG; Kang, SY; Seim, NB; Teknos, TN, 2017) |
| "Radiotherapy is a common approach for treating squamous cell carcinoma (SCC) of the oropharynx." | 1.43 | Treatment: Outcome and Toxicity of Volumetric Modulated Arc Therapy in Oropharyngeal Carcinoma. ( Clerici, E; Cozzi, L; D'Agostino, G; Fogliata, A; Franceschini, D; Franzese, C; Mancosu, P; Navarria, P; Scorsetti, M; Tomatis, S, 2016) |
| "The optimal management of oropharyngeal squamous cell carcinoma (OPSCC) is controversial." | 1.38 | Treatment of oropharyngeal squamous cell carcinoma with IMRT: patterns of failure after concurrent chemoradiotherapy and sequential therapy. ( Annino, DJ; Balboni, TA; Goguen, LA; Haddad, RI; Lorch, J; Norris, CM; Posner, MR; Sher, DJ; Thotakura, V; Tishler, RB, 2012) |
| "Strictures were associated with tumor location (tonsil vs base of tongue; p = ." | 1.37 | Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma. ( Best, SR; Blanco, RG; Califano, JA; Ha, PK; Levine, MA; Messing, BP; Murakami, P; Pai, SI; Saunders, JR; Thompson, R; Trachta, J; Ulmer, K; Walker, M; Zinreich, ES, 2011) |
| "Mucositis was the major acute toxicity, but this was well tolerated in most subjects." | 1.36 | Weekly low-dose docetaxel-based chemoradiotherapy for locally advanced oropharyngeal or hypopharyngeal carcinoma: a retrospective, single-institution study. ( Fujii, M; Fukada, J; Kawaguchi, O; Kubo, A; Kunieda, E; Ohashi, T; Shigematsu, N; Shiotani, A; Takeda, A; Tomita, T, 2010) |
| "Patients receiving C-IMRT for head-and-neck cancer had repeat CT scans at weeks 2, 3, 4, and 5 during radiotherapy." | 1.36 | Weekly volume and dosimetric changes during chemoradiotherapy with intensity-modulated radiation therapy for head and neck cancer: a prospective observational study. ( Barbachano, Y; Bhide, SA; Burke, K; Davies, M; El-Hariry, IA; Hansen, V; Harrington, KJ; McNair, HA; Newbold, K; Nutting, CM, 2010) |
| "The growing number of patients with head and neck cancer is a reason to search for new effective treatment strategies." | 1.36 | [Taxan induction chemotherapy and concomitant chemoradiotherapy with cisplatin in patients with locally advanced head and neck cancer--early results]. ( Chilimoniuk, M; Maksimowicz, T; Olszewska, E, 2010) |
| " The plasma 5-FU level was measured, and adverse events appearing after administration were monitored." | 1.33 | [Pharmacokinetics and adverse event of TS-1 administered through gastrostomy]. ( Hasegawa, M; Hirano, K; Nakamura, K, 2005) |
| "Average survival for advanced head and neck cancer (AHNC) is 18 months." | 1.27 | Pretreatment with chemotherapy in patients with advanced head and neck cancer. ( Barron, P; Cripps, C; Danjoux, C; de la Bastide, Y; Hardie, J; Nichol, J; Odell, P, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (5.26) | 18.7374 |
| 1990's | 26 (22.81) | 18.2507 |
| 2000's | 43 (37.72) | 29.6817 |
| 2010's | 37 (32.46) | 24.3611 |
| 2020's | 2 (1.75) | 2.80 |
| Authors | Studies |
|---|---|
| Bußmann, L | 1 |
| Laban, S | 2 |
| Wittekindt, C | 2 |
| Stromberger, C | 2 |
| Tribius, S | 2 |
| Möckelmann, N | 1 |
| Böttcher, A | 1 |
| Betz, CS | 1 |
| Klussmann, JP | 1 |
| Budach, V | 3 |
| Muenscher, A | 1 |
| Busch, CJ | 1 |
| Bahig, H | 1 |
| Lambert, L | 1 |
| Filion, E | 1 |
| Soulières, D | 3 |
| Guertin, L | 3 |
| Ayad, T | 1 |
| Christopoulos, A | 1 |
| Bissada, E | 1 |
| Alizadeh, M | 1 |
| Bélair, M | 1 |
| Nguyen-Tan, PF | 3 |
| Hess, AK | 1 |
| Müer, A | 1 |
| Mairinger, FD | 1 |
| Weichert, W | 1 |
| Stenzinger, A | 1 |
| Hummel, M | 1 |
| Tinhofer, I | 1 |
| Inhestern, J | 1 |
| Schmalenberg, H | 2 |
| Dietz, A | 6 |
| Rotter, N | 1 |
| Maschmeyer, G | 2 |
| Jungehülsing, M | 1 |
| Grosse-Thie, C | 1 |
| Kuhnt, T | 2 |
| Görner, M | 1 |
| Sudhoff, H | 2 |
| Guntinas-Lichius, O | 3 |
| Benedict, PA | 1 |
| Ruiz, R | 1 |
| Verma, A | 1 |
| Dion, GR | 1 |
| Oh, P | 1 |
| Wang, B | 1 |
| Ahmed, OH | 1 |
| Hiwatashi, N | 1 |
| Bing, R | 1 |
| Victor, K | 1 |
| Hu, KS | 1 |
| Johnson, A | 1 |
| Branski, RC | 1 |
| Amin, MR | 1 |
| Kijima, T | 1 |
| Nakagawa, H | 1 |
| Shimonosono, M | 1 |
| Chandramouleeswaran, PM | 1 |
| Hara, T | 1 |
| Sahu, V | 1 |
| Kasagi, Y | 1 |
| Kikuchi, O | 1 |
| Tanaka, K | 1 |
| Giroux, V | 1 |
| Muir, AB | 1 |
| Whelan, KA | 1 |
| Ohashi, S | 1 |
| Naganuma, S | 1 |
| Klein-Szanto, AJ | 1 |
| Shinden, Y | 1 |
| Sasaki, K | 1 |
| Omoto, I | 1 |
| Kita, Y | 1 |
| Muto, M | 1 |
| Bass, AJ | 1 |
| Diehl, JA | 1 |
| Ginsberg, GG | 1 |
| Doki, Y | 1 |
| Mori, M | 1 |
| Uchikado, Y | 1 |
| Arigami, T | 1 |
| Avadhani, NG | 1 |
| Basu, D | 1 |
| Rustgi, AK | 1 |
| Natsugoe, S | 1 |
| Hall, SF | 1 |
| Griffiths, RJ | 1 |
| O'Sullivan, B | 1 |
| Liu, FF | 1 |
| Maggiore, RJ | 1 |
| Curran, EK | 1 |
| Witt, ME | 1 |
| Haraf, DJ | 1 |
| Vokes, EE | 1 |
| Cohen, EE | 1 |
| Bossi, P | 2 |
| Orlandi, E | 2 |
| Miceli, R | 2 |
| Perrone, F | 1 |
| Guzzo, M | 1 |
| Mariani, L | 2 |
| Granata, R | 2 |
| Locati, L | 2 |
| Fallai, C | 1 |
| Cortelazzi, B | 1 |
| Pilotti, S | 1 |
| Scaramellini, G | 1 |
| Gloghini, A | 1 |
| Licitra, L | 2 |
| Loong, HH | 1 |
| Winquist, E | 1 |
| Waldron, J | 1 |
| Chen, EX | 1 |
| Kim, J | 1 |
| Palma, D | 1 |
| Read, N | 1 |
| Razak, AR | 1 |
| Diaz-Padilla, I | 1 |
| Chan, K | 2 |
| Bayley, A | 1 |
| Hossain, M | 1 |
| Wang, L | 1 |
| Chin, S | 1 |
| Siu, LL | 1 |
| Hope, A | 1 |
| Hasegawa, M | 2 |
| Maeda, H | 1 |
| Deng, Z | 1 |
| Kiyuna, A | 1 |
| Ganaha, A | 1 |
| Yamashita, Y | 1 |
| Matayoshi, S | 1 |
| Agena, S | 1 |
| Toita, T | 1 |
| Uehara, T | 1 |
| Suzuki, M | 2 |
| Wakisaka, N | 1 |
| Yoshida, S | 1 |
| Kondo, S | 1 |
| Kita, M | 1 |
| Endo, K | 1 |
| Tsuji, A | 1 |
| Murono, S | 1 |
| Muramatsu, M | 1 |
| Yoshizaki, T | 1 |
| Poettgen, C | 1 |
| Baumann, M | 1 |
| Budach, W | 1 |
| Grabenbauer, G | 1 |
| Marnitz, S | 1 |
| Olze, H | 1 |
| Wernecke, KD | 1 |
| Ghadjar, P | 1 |
| Chibaudel, B | 1 |
| Lacave, R | 1 |
| Lefevre, M | 1 |
| Soussan, P | 1 |
| Antoine, M | 1 |
| Périé, S | 1 |
| Belloc, JB | 1 |
| Banal, A | 1 |
| Albert, S | 1 |
| Chabolle, F | 1 |
| Céruse, P | 1 |
| Baril, P | 1 |
| Gatineau, M | 1 |
| Housset, M | 1 |
| Moukoko, R | 1 |
| Benetkiewicz, M | 1 |
| de Gramont, A | 1 |
| Bonnetain, F | 1 |
| Lacau St Guily, J | 2 |
| Asakage, T | 2 |
| Ando, M | 1 |
| Yoshida, M | 1 |
| Saito, Y | 1 |
| Omura, G | 1 |
| Yamasoba, T | 1 |
| Schmaltz, H | 1 |
| Borel, C | 1 |
| Ciftci, S | 1 |
| Takeda-Raguin, C | 1 |
| Debry, C | 1 |
| Schultz, P | 1 |
| Dupret-Bories, A | 1 |
| Franzese, C | 1 |
| Fogliata, A | 1 |
| Franceschini, D | 1 |
| Clerici, E | 1 |
| D'Agostino, G | 1 |
| Navarria, P | 1 |
| Mancosu, P | 1 |
| Tomatis, S | 1 |
| Cozzi, L | 1 |
| Scorsetti, M | 1 |
| Bergamini, C | 1 |
| Cova, A | 1 |
| Resteghini, C | 1 |
| Alfieri, S | 1 |
| Imbimbo, M | 1 |
| Iacovelli, NA | 1 |
| Huber, V | 1 |
| Cavallo, A | 1 |
| Rivoltini, L | 1 |
| Seim, NB | 1 |
| Kang, SY | 1 |
| Bhandari, M | 1 |
| Jones, RG | 1 |
| Teknos, TN | 2 |
| Finnegan, V | 1 |
| Parsons, JT | 2 |
| Greene, BD | 1 |
| Sharma, V | 1 |
| Lee, N | 2 |
| Nehmeh, S | 1 |
| Schöder, H | 1 |
| Fury, M | 1 |
| Ling, CC | 1 |
| Humm, J | 1 |
| Gupta, D | 1 |
| Shukla, P | 1 |
| Bisht, SS | 1 |
| Dhawan, A | 1 |
| Pant, MC | 1 |
| Bhatt, ML | 1 |
| Gupta, S | 1 |
| Gupta, R | 1 |
| Negi, MP | 1 |
| Nguyen, NP | 1 |
| Frank, C | 1 |
| Moltz, CC | 1 |
| Vos, P | 1 |
| Smith, HJ | 1 |
| Nguyen, PD | 1 |
| Martinez, T | 1 |
| Karlsson, U | 1 |
| Dutta, S | 1 |
| Lemanski, C | 2 |
| Nguyen, LM | 1 |
| Sallah, S | 1 |
| Fukada, J | 1 |
| Shigematsu, N | 1 |
| Takeda, A | 1 |
| Ohashi, T | 1 |
| Tomita, T | 1 |
| Shiotani, A | 1 |
| Kunieda, E | 1 |
| Kawaguchi, O | 1 |
| Fujii, M | 3 |
| Kubo, A | 1 |
| Barkati, M | 1 |
| Fortin, B | 2 |
| Clavel, S | 2 |
| Després, P | 2 |
| Charpentier, D | 1 |
| Tabet, JC | 1 |
| Olivier, MJ | 1 |
| Coulombe, G | 1 |
| Donath, D | 2 |
| Nakamura, T | 1 |
| Kodaira, T | 2 |
| Tachibana, H | 1 |
| Tomita, N | 1 |
| Yokouchi, J | 1 |
| Fuwa, N | 2 |
| Klug, C | 4 |
| Berzaczy, D | 1 |
| Voracek, M | 3 |
| Nell, C | 1 |
| Ploder, O | 2 |
| Millesi, W | 5 |
| Ewers, R | 4 |
| Oikawa, H | 1 |
| Nakamura, R | 1 |
| Nakasato, T | 1 |
| Nishimura, K | 1 |
| Sato, H | 1 |
| Ehara, S | 1 |
| Shueng, PW | 1 |
| Wu, LJ | 1 |
| Chen, SY | 1 |
| Hsiao, CH | 1 |
| Tien, HJ | 1 |
| Cheng, PW | 1 |
| Kuo, YS | 1 |
| Chen, YJ | 1 |
| Chen, CA | 1 |
| Hsieh, PY | 1 |
| Hsieh, CH | 1 |
| Hillel, AT | 1 |
| Fakhry, C | 1 |
| Pai, SI | 2 |
| Williams, MF | 1 |
| Blanco, RG | 2 |
| Zinreich, ES | 2 |
| Levine, MA | 2 |
| Westra, WH | 1 |
| Saunders, JR | 2 |
| Ha, PK | 2 |
| Bhide, SA | 1 |
| Davies, M | 1 |
| Burke, K | 1 |
| McNair, HA | 1 |
| Hansen, V | 1 |
| Barbachano, Y | 1 |
| El-Hariry, IA | 1 |
| Newbold, K | 1 |
| Harrington, KJ | 1 |
| Nutting, CM | 1 |
| Christiansen, H | 1 |
| Rödel, RM | 1 |
| Matthias, C | 1 |
| Hess, CF | 2 |
| Wolff, HA | 1 |
| Boscolo-Rizzo, P | 1 |
| Gava, A | 1 |
| Baggio, V | 1 |
| Marchiori, C | 1 |
| Stellin, M | 1 |
| Fuson, R | 1 |
| Lamon, S | 1 |
| Da Mosto, MC | 1 |
| Habl, G | 2 |
| Jensen, AD | 2 |
| Potthoff, K | 2 |
| Uhl, M | 1 |
| Hof, H | 1 |
| Hajda, J | 1 |
| Simon, C | 1 |
| Debus, J | 2 |
| Krempien, R | 1 |
| Münter, MW | 2 |
| Best, SR | 1 |
| Walker, M | 1 |
| Trachta, J | 1 |
| Ulmer, K | 1 |
| Murakami, P | 1 |
| Thompson, R | 1 |
| Califano, JA | 1 |
| Messing, BP | 1 |
| Nguyen, DH | 1 |
| Khaouam, N | 1 |
| Chilimoniuk, M | 1 |
| Olszewska, E | 1 |
| Maksimowicz, T | 1 |
| Krauss, J | 1 |
| Desta, A | 1 |
| Mavtratzas, A | 1 |
| Windemuth-Kiesselbach, C | 1 |
| Nishio, R | 1 |
| Saito, K | 1 |
| Ito, H | 1 |
| Yoshida, T | 1 |
| Kitamura, K | 1 |
| Shimizu, A | 1 |
| Kanesaka, N | 1 |
| Mikami, R | 1 |
| Hasegawa, D | 1 |
| Tokuuye, K | 1 |
| Sanguineti, G | 1 |
| Sormani, MP | 1 |
| Marur, S | 1 |
| Gunn, GB | 1 |
| Rao, N | 1 |
| Cianchetti, M | 1 |
| Ricchetti, F | 1 |
| McNutt, T | 1 |
| Wu, B | 1 |
| Forastiere, A | 1 |
| Wang, CJ | 1 |
| Münscher, A | 1 |
| Schafhausen, P | 1 |
| Knecht, R | 1 |
| Sher, DJ | 1 |
| Thotakura, V | 1 |
| Balboni, TA | 1 |
| Norris, CM | 1 |
| Haddad, RI | 1 |
| Posner, MR | 1 |
| Lorch, J | 1 |
| Goguen, LA | 1 |
| Annino, DJ | 1 |
| Tishler, RB | 1 |
| Tomita, M | 1 |
| Matsuyama, H | 1 |
| Yamazaki, K | 1 |
| Sato, K | 1 |
| Takahashi, S | 1 |
| Masterson, L | 1 |
| Tanweer, F | 1 |
| Loo, SW | 1 |
| Geropantas, K | 1 |
| Wilson, P | 1 |
| Martin, WM | 1 |
| Roques, TW | 1 |
| Perisanidis, C | 1 |
| Sulzbacher, I | 2 |
| Mittlböck, M | 1 |
| Mitchell, D | 1 |
| Czembirek, C | 1 |
| Seemann, R | 1 |
| Schopper, C | 1 |
| Selzer, E | 4 |
| Oertel, K | 1 |
| Spiegel, K | 1 |
| Wendt, TG | 1 |
| Neuburg, J | 1 |
| Glaser, C | 2 |
| Schwarz, B | 1 |
| Kermer, C | 3 |
| Schmidberger, H | 1 |
| Rave-Fränk, M | 1 |
| Kim, S | 1 |
| Hille, A | 1 |
| Pradier, O | 1 |
| Kovács, AF | 1 |
| Ghahremani, MT | 1 |
| Stefenelli, U | 1 |
| Bitter, K | 1 |
| Helbig, M | 1 |
| Schlemmer, HP | 1 |
| Lumer, M | 1 |
| Knopp, MV | 1 |
| Denis, F | 1 |
| Garaud, P | 1 |
| Bardet, E | 2 |
| Alfonsi, M | 2 |
| Sire, C | 2 |
| Germain, T | 2 |
| Bergerot, P | 2 |
| Rhein, B | 3 |
| Tortochaux, J | 3 |
| Calais, G | 7 |
| Watanabe, A | 1 |
| Taniguchi, M | 1 |
| Rodriguez-Pinilla, M | 1 |
| Rodriguez-Peralto, JL | 1 |
| Hitt, R | 1 |
| Sanchez, JJ | 1 |
| Ballestin, C | 1 |
| Diez, A | 1 |
| Sanchez-Verde, L | 1 |
| Alameda, F | 1 |
| Sanchez-Cespedes, M | 1 |
| Wutzl, A | 2 |
| Kornek, G | 1 |
| Poeschl, PW | 1 |
| Oeckher, M | 1 |
| de Arruda, FF | 1 |
| Puri, DR | 2 |
| Zhung, J | 1 |
| Narayana, A | 1 |
| Wolden, S | 1 |
| Hunt, M | 1 |
| Stambuk, H | 1 |
| Pfister, D | 1 |
| Kraus, D | 1 |
| Shaha, A | 1 |
| Shah, J | 1 |
| Lee, NY | 1 |
| Hirano, K | 1 |
| Nakamura, K | 1 |
| Yom, SS | 1 |
| Machtay, M | 1 |
| Biel, MA | 1 |
| Sinard, RJ | 1 |
| El-Naggar, AK | 1 |
| Weber, RS | 1 |
| Rosenthal, DI | 1 |
| Chou, W | 1 |
| Nijdam, W | 1 |
| Levendag, P | 1 |
| Noever, I | 1 |
| Groot, CU | 1 |
| Agthoven, Mv | 1 |
| Bensadoun, RJ | 3 |
| Bénézery, K | 1 |
| Dassonville, O | 3 |
| Magné, N | 2 |
| Poissonnet, G | 2 |
| Ramaïoli, A | 1 |
| Bourdin, S | 2 |
| Peyrade, F | 1 |
| Marcy, PY | 3 |
| Chamorey, E | 2 |
| Vallicioni, J | 2 |
| Seng, H | 1 |
| Alzieu, C | 1 |
| Géry, B | 1 |
| Chauvel, P | 2 |
| Schneider, M | 4 |
| Santini, J | 2 |
| Demard, F | 5 |
| Semrau, R | 1 |
| Mueller, RP | 2 |
| Stuetzer, H | 2 |
| Staar, S | 2 |
| Schroeder, U | 1 |
| Kocher, M | 1 |
| Eich, HT | 1 |
| Flentje, M | 3 |
| Rudat, V | 2 |
| Volling, P | 3 |
| Schroeder, M | 2 |
| Eckel, HE | 2 |
| Spencker, S | 1 |
| Schmittel, A | 1 |
| Westermann, D | 1 |
| Marek, A | 1 |
| Schultheiss, HP | 1 |
| Witzenbichler, B | 1 |
| Ijuin, T | 1 |
| Nibu, K | 1 |
| Doi, K | 1 |
| Inoue, H | 1 |
| Saitoh, M | 1 |
| Ohtsuki, N | 1 |
| Makino, K | 1 |
| Amatsu, M | 1 |
| Vikhlianov, IV | 2 |
| Shoĭket, IaN | 1 |
| Lazarev, AF | 2 |
| Kawashima, M | 1 |
| Fujii, H | 1 |
| Hayashi, R | 1 |
| Tahara, M | 1 |
| Nasu, K | 1 |
| Arahira, S | 1 |
| Ogino, T | 1 |
| Kikuta, S | 1 |
| Nakao, K | 1 |
| Sugasawa, M | 1 |
| Kubota, A | 2 |
| Wadasaki, K | 1 |
| Matsuura, K | 1 |
| Murakami, Y | 1 |
| Kenjo, M | 1 |
| Kaneyasu, Y | 1 |
| Fujita, M | 1 |
| Ito, K | 1 |
| Tatsukawa, R | 1 |
| Takeno, Y | 1 |
| Hirakawa, K | 1 |
| Furukawa, M | 1 |
| Hanamura, H | 1 |
| Fujita, Y | 1 |
| Sugiyama, M | 1 |
| Shoĭkhet, IaN | 1 |
| Keilholz, U | 1 |
| Werner, J | 1 |
| Hagen, R | 1 |
| Iro, H | 2 |
| Worden, FP | 1 |
| Kumar, B | 1 |
| Lee, JS | 1 |
| Wolf, GT | 2 |
| Cordell, KG | 1 |
| Taylor, JM | 1 |
| Urba, SG | 2 |
| Eisbruch, A | 2 |
| Chepeha, DB | 1 |
| Prince, ME | 1 |
| Tsien, CI | 1 |
| D'Silva, NJ | 1 |
| Yang, K | 1 |
| Kurnit, DM | 1 |
| Mason, HL | 1 |
| Miller, TH | 1 |
| Wallace, NE | 1 |
| Bradford, CR | 2 |
| Carey, TE | 1 |
| Loré, JM | 1 |
| Diaz-Ordaz, E | 1 |
| Spaulding, M | 1 |
| Chary, K | 1 |
| Kaufman, S | 1 |
| Lawrence, W | 1 |
| Hong, F | 1 |
| Gerold, T | 1 |
| Sundquist, N | 1 |
| Barrali, RA | 1 |
| Etienne, MC | 2 |
| Milano, G | 2 |
| Thyss, A | 2 |
| Otto, J | 1 |
| Mobayen, H | 1 |
| Saudes, L | 1 |
| Guillot, T | 1 |
| Schröder, M | 1 |
| Reisser, C | 1 |
| Haberkorn, U | 2 |
| Dimitrakopoulou-Strauss, A | 1 |
| Seifert, E | 2 |
| Strauss, LG | 2 |
| Gedouin, D | 1 |
| Desprez, P | 1 |
| Perron, JJ | 1 |
| Fleury, F | 1 |
| Leclech, G | 1 |
| Miglianico, L | 1 |
| Belpomme, D | 1 |
| Chenal, C | 1 |
| Berger, C | 2 |
| Chapet, S | 2 |
| Reynaud-Bougnoux, A | 3 |
| Garand, G | 3 |
| le Floch, O | 3 |
| del Campo, JM | 2 |
| Felip, E | 1 |
| Giralt, J | 1 |
| Raspall, G | 2 |
| Bescos, S | 2 |
| Casado, S | 1 |
| Maldonado, X | 1 |
| Santa Cruz Ruiz, S | 1 |
| Gómez González, JL | 1 |
| Flores Corral, T | 1 |
| Del Cañizo Alvarez, A | 1 |
| Deleyiannis, FW | 1 |
| Weymuller, EA | 1 |
| Coltrera, MD | 1 |
| Fujieda, S | 2 |
| Sunaga, H | 2 |
| Tsuzuki, H | 2 |
| Tanaka, N | 2 |
| Saito, H | 2 |
| El Amrani, M | 1 |
| Heinzlef, O | 1 |
| Debroucker, T | 1 |
| Roullet, E | 1 |
| Bousser, MG | 1 |
| Amarenco, P | 1 |
| Pivot, X | 2 |
| Prevost, B | 1 |
| Coche-Dequeant, B | 2 |
| Courdi, A | 1 |
| Teissier, E | 1 |
| Lagrange, JL | 1 |
| Bieri, S | 1 |
| Allal, AS | 1 |
| Dulguerov, P | 1 |
| Lehmann, W | 1 |
| Kurtz, JM | 1 |
| Nathu, RM | 1 |
| Mendenhall, WM | 1 |
| Mancuso, AA | 1 |
| Carroll, RR | 1 |
| Noda, I | 1 |
| Sugimoto, C | 1 |
| Oudinot, P | 1 |
| Bertrand, P | 1 |
| Giralt, JL | 1 |
| Gonzalez, J | 1 |
| Maldonado, J | 1 |
| Sanz, X | 1 |
| Pamias, J | 1 |
| Eraso, A | 1 |
| Thornton, AF | 1 |
| Terrell, JE | 1 |
| Carpenter, V | 1 |
| Miller, T | 1 |
| Tang, G | 1 |
| Strawderman, M | 1 |
| Sasaoka, M | 1 |
| Matsumoto, A | 1 |
| Kimura, Y | 1 |
| Furutani, K | 1 |
| Kamata, M | 1 |
| Morita, K | 1 |
| Domenge, C | 1 |
| Hill, C | 1 |
| Lefebvre, JL | 1 |
| De Raucourt, D | 1 |
| Wibault, P | 1 |
| Marandas, P | 1 |
| Stromboni-Luboinski, M | 1 |
| Sancho-Garnier, H | 1 |
| Luboinski, B | 1 |
| Glaser, CM | 1 |
| Kornek, GV | 1 |
| Lang, S | 1 |
| Schüll, B | 1 |
| Watzinger, F | 1 |
| Lavey, RS | 1 |
| Guardiola, E | 1 |
| Yamashita, T | 1 |
| Ishiguro, R | 1 |
| Tashiro, M | 1 |
| Ohno, Y | 1 |
| Ma, B | 1 |
| Corry, J | 1 |
| Rischin, D | 1 |
| Leong, T | 1 |
| Peters, LJ | 1 |
| Bauer, FP | 1 |
| Westhofen, M | 1 |
| Schadel, A | 1 |
| Welkoborsky, HJ | 1 |
| Bleier, R | 1 |
| Wissen-Siegert, I | 1 |
| Beutter, P | 1 |
| Fietkau, R | 1 |
| Grabenbauer, GG | 1 |
| Altendorf-Hofmann, A | 1 |
| Sauer, R | 1 |
| Dobrowsky, W | 4 |
| Dobrowsky, E | 3 |
| Strassl, H | 4 |
| Braun, O | 3 |
| Gritzmann, N | 1 |
| Scheiber, V | 2 |
| Schratter-Sehn, AU | 1 |
| Handl-Zeller, L | 1 |
| Braun, OM | 1 |
| Mende, U | 1 |
| Zöller, J | 1 |
| Drommer, RB | 1 |
| Reichardt, P | 1 |
| Born, IA | 1 |
| Laccourreye, H | 1 |
| Bassot, V | 1 |
| Brasnu, D | 1 |
| Menard, M | 1 |
| Donnadieu, S | 1 |
| Jacquillat, C | 1 |
| Inuyama, Y | 1 |
| Tanaka, J | 1 |
| Takaoka, T | 1 |
| Hosoda, H | 1 |
| Kohno, N | 1 |
| Cripps, C | 1 |
| Odell, P | 1 |
| Danjoux, C | 1 |
| Nichol, J | 1 |
| de la Bastide, Y | 1 |
| Barron, P | 1 |
| Hardie, J | 1 |
| Goga, D | 1 |
| Le Flock, O | 1 |
| Ballon, G | 1 |
| Rausch, EM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparative Effectiveness Trial of Transoral Head and Neck Surgery Followed by Adjuvant Radio(Chemo)Therapy Versus Primary Radiochemotherapy for Oropharyngeal Cancer[NCT03691441] | Phase 4 | 280 participants (Anticipated) | Interventional | 2018-01-05 | Active, not recruiting | ||
| Phase I/II Study of Split-dose TPF-Induction Chemotherapy Before Surgery of Oropharyngeal and Cavity of the Mouth Cancer[NCT01108042] | Phase 1/Phase 2 | 71 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| Phase I Trial of ABI-007 (Abraxane) Plus Cisplatin Plus 5-Fluorouracil (APF) as Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Patients With Locally Advanced Squamous Cell Cancers of the Head and Neck (HNSCC)[NCT00731380] | Phase 1 | 12 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Microbiota, Inflammatory Environment, Clinical and Radiomic Features as Predictors of Normal Tissue Response in Radiotherapy for Prostate and Head-and-neck Cancer[NCT03294122] | 400 participants (Anticipated) | Observational | 2017-02-02 | Recruiting | |||
| Quarterback 22: A Phase II Clinical Trial of Sequential Therapy and De-Intensified Chemoradiotherapy for Locally Advanced HPV Positive Oropharynx Cancer[NCT02945631] | 43 participants (Actual) | Interventional | 2016-04-25 | Active, not recruiting | |||
| The Quarterback Trial: A Randomized Phase III Clinical Trial Comparing Reduced and Standard Radiation Therapy Doses for Locally Advanced HPV Positive Oropharynx Cancer[NCT01706939] | Phase 3 | 23 participants (Actual) | Interventional | 2012-09-01 | Active, not recruiting | ||
| A Clinical Outcomes Protocol of Photon/Proton Beam Radiation Therapy for Oropharyngeal Cancers[NCT00797446] | 10 participants (Actual) | Observational | 2007-09-30 | Terminated (stopped due to Slow enrollment, feasibility issues) | |||
| Phase III Randomized Study of Radiotherapy With or Without Cisplatin and Fluorouracil for Locally Advanced, Nonresectable Squamous Cell Cancer of the Oropharynx or Hypopharynx[NCT00003627] | Phase 3 | 160 participants (Anticipated) | Interventional | 1998-10-31 | Completed | ||
| The Effect of Prophylactic Swallowing Exercises on Head and Neck Cancer Patients[NCT01349309] | 26 participants (Actual) | Interventional | 2007-06-30 | Completed | |||
| Phase I Study of Cabazitaxel - Platinum Fluorouracil Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck[NCT01379339] | Phase 1 | 40 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| Radiosensitization With a COX-2 Inhibitor (Celecoxib), With Chemoradiation for Cancer of the Head and Neck[NCT00581971] | Phase 1/Phase 2 | 30 participants (Actual) | Interventional | 2002-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To determine biomarkers predictive of failure with either reduced or standard dose radiotherapy. (NCT01706939)
Timeframe: at 5 years
| Intervention | biomarkers (Number) |
|---|---|
| Reduced Dose Radiation | 0 |
| Standard Dose Radiation | 0 |
MDADI is a questionnaire of 20 questions and contains a global subscale, and three other categories of questions (emotional, functional, and physical). The scores are summed and a mean score is calculated. This mean score was multiplied by 20 to obtain a score, with a range of 0 (extremely low functioning) to 100 (high functioning). Thus, a higher MDADI score represented better day-to-day functioning and better QOL. (NCT01706939)
Timeframe: Baseline and 5 years
| Intervention | score on a scale (Mean) |
|---|---|
| Reduced Dose Radiation | -8.12 |
| Standard Dose Radiation | -8.93 |
XQ is a nine questions survey developed specifically for xerostomia symptoms. The scores are summed and a mean score is calculated on a scale of 0 (low xerostomia interference) to 10 (high xerostomia interference). A lower or negative score reflects a better quality of life compared to baseline. (NCT01706939)
Timeframe: Baseline and 5 years
| Intervention | score on a scale (Mean) |
|---|---|
| Reduced Dose Radiation | 2.18 |
| Standard Dose Radiation | 4.38 |
Number of participants with acute toxicity treated with reduced or standard dose CRT. (NCT01706939)
Timeframe: at 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Reduced Dose Radiation | 3 |
| Standard Dose Radiation | 1 |
Local-regional control (LRC) at 3 years in patients with advanced HPV related oropharynx cancer or unknown primary treated with reduced or standard dose radiation. (NCT01706939)
Timeframe: at 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Reduced Dose Radiation | 10 |
| Standard Dose Radiation | 7 |
Overall Survival (OS) 5 years treated with reduced or standard dose CRT. (NCT01706939)
Timeframe: at 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Reduced Dose Radiation | 10 |
| Standard Dose Radiation | 7 |
The EORTC Head and Neck module was specifically designed and validated for head and neck cancer patients. This 35-item questionnaire contains 7 symptom scales (pain, swallowing, senses, speech, social eating, social contact, and sexuality), 6 single-item scales (difficulties of teeth, mouth opening, dry mouth, sticky saliva, coughing, and feeling ill), and 5 items about the additional use of pain medicine, nutritional supplements, and feeding tube and changes in body weight. All items were transformed to scales from 0 to 100, and divided into respective sub-scores of global health (GHS), functional (FS), and symptom scale (SS). Subscales from 0-100. A high score on global health and functional scale represents a better level of functioning, whereas a high score on a symptom scale and head and neck module indicates more severe symptoms. (NCT01706939)
Timeframe: Baseline and 5 years
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| EORTC GHS | EORTC FS | EORTC SS | EORTC HN | |
| Reduced Dose Radiation | 5.95 | 5.14 | -3.91 | -2.80 |
| Standard Dose Radiation | -30.56 | -6.33 | 14.97 | 8.97 |
"MD Anderson Symptom Inventory Symptom Inventory and Severity (MDASI-HN SI and SS) MDASI Head and Neck is a site-specific MDASI module which includes the core MDASI 13 symptom severity items (SS) and 6 symptom interference items (SI), alongside 9 items relevant to head and neck cancer. The scores are summed and a mean score is calculated on a scale of 0 (low severity or interference) to 10 (high severity or complete interference). In order to calculate the mean score, a majority of the subscale's items must have been completed.~A lower or negative score reflects a better quality of life compared to baseline." (NCT01706939)
Timeframe: Baseline and 5 years
| Intervention | score on a scale (Mean) | |
|---|---|---|
| MDASI-HN SI | MDASI-HN SS | |
| Reduced Dose Radiation | 0.64 | 0.52 |
| Standard Dose Radiation | 1.56 | 1.48 |
Progression free survival (PFS) at 5 years in patients with advanced HPV related oropharynx cancer, nasopharynx cancer or unknown primary treated with reduced or standard dose radiation. (NCT01706939)
Timeframe: at 3 and 5 years
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| at 3 years | at 5 years | |
| Reduced Dose Radiation | 10 | 10 |
| Standard Dose Radiation | 7 | 7 |
Evaluate the response to concurrent celecoxib, carboplatin, paclitaxel, and radiotherapy in the treatment of locally advanced SSC of the head and neck. Response is determined by local control only, local and distant metastasis, distant metastasis only, second primary, and surgical salvage. (NCT00581971)
Timeframe: 2 years from end of treatment (Radiation therapy)
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Local Control Only | Local Control and Distant Metastasis | Distant Metastatsis Only | Secondary Primary - Site Unknown | Surgical Salvage | |
| Recurrence | 6 | 2 | 1 | 2 | 3 |
Particpants experiencing Acute Toxicities > Grade 3 (NCT00581971)
Timeframe: 2 years from radiation therapy
| Intervention | participants (Number) | ||
|---|---|---|---|
| Hematologic | Dermatitis | Mucositis/Dysphagia | |
| Acute Toxicity | 12 | 7 | 16 |
5 reviews available for fluorouracil and Cancer of Oropharnyx
| Article | Year |
|---|---|
Molecular targeting agents in the context of primary chemoradiation strategies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineo | 2013 |
[Current role for induction chemotherapy in head and neck tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2008 |
[Concomitant radiochemotherapy with cisplatin (CDDP), 5-fluorouracil (5-FU) and mitomycin C (MMC) in locally advanced carcinoma of the oropharynx. Results of a phase II trial].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1995 |
[Update on cancerology of the upper aerodigestive tract].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Transplantation; Clinical Tr | 1998 |
Combined modality treatment for locally advanced squamous-cell carcinoma of the oropharynx in a woman with Bloom's syndrome: a case report and review of the literature.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bloom Syndro | 2001 |
30 trials available for fluorouracil and Cancer of Oropharnyx
| Article | Year |
|---|---|
Comparative effectiveness trial of transoral head and neck surgery followed by adjuvant radio(chemo)therapy versus primary radiochemotherapy for oropharyngeal cancer (TopROC).
Topics: Adult; Antineoplastic Agents; Carcinoma, Squamous Cell; Cause of Death; Chemoradiotherapy, Adjuvant; | 2020 |
Phase II study of de-intensified intensity-modulated radiotherapy and concurrent carboplatin/5-fluorouracil in lateralized p16-associated oropharyngeal carcinoma.
Topics: Carboplatin; Carcinoma, Squamous Cell; Fluorouracil; Humans; Oropharyngeal Neoplasms; Radiotherapy D | 2020 |
MiR-200b and miR-155 as predictive biomarkers for the efficacy of chemoradiation in locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemoradiotherapy; C | 2017 |
A two-arm multicenter phase II trial of one cycle chemoselection split-dose docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy before two cycles of split TPF followed by curative surgery combined with postoperative radiotherapy in patien
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2017 |
Phase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the oropharynx.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2014 |
HPV Status Determines the Efficacy of Adjuvant Chemotherapy With S-1, an Oral Fluorouracil Prodrug, in Oropharyngeal Cancer.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinatio | 2015 |
Hyperfractionated accelerated radiation therapy (HART) of 70.6 Gy with concurrent 5-FU/Mitomycin C is superior to HART of 77.6 Gy alone in locally advanced head and neck cancer: long-term results of the ARO 95-06 randomized phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2015 |
Induction therapy with cetuximab plus docetaxel, cisplatin, and 5-fluorouracil (ETPF) in patients with resectable nonmetastatic stage III or IV squamous cell carcinoma of the oropharynx. A GERCOR phase II ECHO-07 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Doce | 2015 |
A prospective comparision of sequential chemoradiation vs concurrent chemoradiation in locally advanced oropharyngeal carcinomas.
Topics: Adult; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Thera | 2009 |
Treatment of locally advanced carcinomas of head and neck with intensity-modulated radiation therapy (IMRT) in combination with cetuximab and chemotherapy: the REACH protocol.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2010 |
Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx--TPF-C-HIT.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
Phase I trial of split-dose induction docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1)
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2012 |
Postoperative chemotherapy with cisplatin and 5-fluorouracil in cancer of the oral cavity and the oropharynx--long-term results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2003 |
Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2004 |
French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2006 |
Efficacy of intensified hyperfractionated and accelerated radiotherapy and concurrent chemotherapy with carboplatin and 5-fluorouracil: updated results of a randomized multicentric trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; | 2006 |
[Means of improvement of surgical treatment for oropharyngeal planocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2007 |
Improved survival with preoperative chemotherapy followed by resection uncompromised by tumor response for advanced squamous cell carcinoma of the head and neck.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1995 |
Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1995 |
[Preliminary results of a prospective randomized study of primary chemotherapy in carcinoma of the oral cavity and pharynx].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squ | 1995 |
[Cancers of the base of the tongue and hypopharynx: results of a multicenter randomized trial of chemotherapy prior to locoregional treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Female; Fluoro | 1996 |
[Concomitant radiochemotherapy with cisplatin (CDDP), 5-fluorouracil (5-FU) and mitomycin C (MMC) in locally advanced carcinoma of the oropharynx. Results of a phase II trial].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1995 |
Preoperative simultaneous chemoradiotherapy in locally advanced cancer of the oral cavity and oropharynx.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1997 |
Concomitant b.i.d. radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in unresectable squamous-cell carcinoma of the pharynx: clinical and pharmacological data of a French multicenter phase II study.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 1998 |
Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carbop | 1999 |
Preoperative induction chemotherapy followed by concurrent chemoradiotherapy in advanced carcinoma of the oral cavity and oropharynx.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Feasibility Studies; Femal | 2000 |
Neoadjuvant therapy for organ preservation in head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Chemot | 2000 |
Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tête et du Cou (GETTEC).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuv | 2000 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
[Induction chemotherapy of carcinomas of the oral cavity and oropharynx. Feasibility study, levels and factors of response to treatment. Apropos of 135 cases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cisplatin; Clinic | 1987 |
80 other studies available for fluorouracil and Cancer of Oropharnyx
| Article | Year |
|---|---|
The effects of concurrent chemoradiation therapy to the base of tongue in a preclinical model.
Topics: Animals; Antineoplastic Agents; Chemoradiotherapy; Cisplatin; Disease Models, Animal; Dose Fractiona | 2018 |
Three-Dimensional Organoids Reveal Therapy Resistance of Esophageal and Oropharyngeal Squamous Cell Carcinoma Cells.
Topics: Animals; Autophagy; Biopsy; Carcinoma, Squamous Cell; Cell Line, Tumor; Chemoradiotherapy; Drug Resi | 2019 |
The addition of chemotherapy to radiotherapy did not reduce the rate of distant metastases in low-risk HPV-related oropharyngeal cancer in a real-world setting.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiothe | 2019 |
Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Che | 2013 |
Treatment-related outcome of oropharyngeal cancer patients differentiated by HPV dictated risk profile: a tertiary cancer centre series analysis.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2014 |
Prediction of concurrent chemoradiotherapy outcome in advanced oropharyngeal cancer.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Female; Fluorouracil; Human Papillomavirus | 2014 |
[Retrospective Study of Induction Chemotherapy and Concurrent Chemoradiation Therapy for Oropharyngeal Cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel | 2015 |
Induction chemotherapy before surgery for unresectable head and neck cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuxi | 2016 |
Treatment: Outcome and Toxicity of Volumetric Modulated Arc Therapy in Oropharyngeal Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2016 |
Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Carcinoma, | 2016 |
Personalized Medicine Approach for an Exceptional Response to Multiple-recurrent and Metastatic HER2-positive Oropharyngeal Squamous Cell Carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cet | 2017 |
Neoadjuvant chemotherapy followed by concurrent hyperfractionated radiation therapy and sensitizing chemotherapy for locally advanced (T3-T4) oropharyngeal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Coh | 2009 |
Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Hypoxia; Cisplatin; Combined | 2009 |
Analysis of factors influencing aspiration risk following chemoradiation for oropharyngeal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Barium Sulfat | 2009 |
Weekly low-dose docetaxel-based chemoradiotherapy for locally advanced oropharyngeal or hypopharyngeal carcinoma: a retrospective, single-institution study.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined | 2010 |
Concurrent chemoradiation with carboplatin-5-fluorouracil versus cisplatin in locally advanced oropharyngeal cancers: is more always better?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2010 |
Clinical outcome of oropharyngeal carcinoma treated with platinum-based chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplat | 2009 |
Preoperative radiochemotherapy in the treatment of advanced oral cancer: outcome of 276 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cohort Studie | 2009 |
Radiotherapy and concomitant intra-arterial docetaxel combined with systemic 5-fluorouracil and cisplatin for oropharyngeal cancer: a preliminary report--improvement of locoregional control of oropharyngeal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2009 |
Concurrent chemoradiotherapy with helical tomotherapy for oropharyngeal cancer: a preliminary result.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2010 |
Selective versus comprehensive neck dissection after chemoradiation for advanced oropharyngeal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chi-Square Distribution; C | 2009 |
Weekly volume and dosimetric changes during chemoradiotherapy with intensity-modulated radiation therapy for head and neck cancer: a prospective observational study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Stem; Cisplatin; Combined Modality Therapy; Fl | 2010 |
In regards to Barkati et al. (Int J Radiat Oncol Biol Phys 2010;76:410-416).
Topics: Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Fluorouracil; He | 2010 |
Matched survival analysis in patients with locoregionally advanced resectable oropharyngeal carcinoma: platinum-based induction and concurrent chemoradiotherapy versus primary surgical resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2011 |
Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2011 |
Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2011 |
Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2011 |
Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2011 |
Simultaneous integrated boost using intensity-modulated radiotherapy compared with conventional radiotherapy in patients treated with concurrent carboplatin and 5-fluorouracil for locally advanced oropharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2012 |
[Taxan induction chemotherapy and concomitant chemoradiotherapy with cisplatin in patients with locally advanced head and neck cancer--early results].
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplat | 2010 |
Selective intraarterial chemoradiation therapy for oropharyngeal carcinoma with high-dose cisplatin.
Topics: Adult; Aged; Angiography; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Contrast Medi | 2011 |
Effect of radiotherapy and chemotherapy on the risk of mucositis during intensity-modulated radiation therapy for oropharyngeal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2012 |
Treatment of oropharyngeal squamous cell carcinoma with IMRT: patterns of failure after concurrent chemoradiotherapy and sequential therapy.
Topics: Aged; Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal; Antineoplastic Combined Chemothera | 2012 |
[Concurrent chemoradiotherapy with either CDDP or CDGP, plus 5-FU for squamous cell carcinoma of the oropharynx and hypopharynx].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2012 |
The role of sequential chemoradiation for local advanced oropharyngeal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2013 |
Target volume definition for intensity-modulated radiotherapy after induction chemotherapy and patterns of treatment failure after sequential chemoradiotherapy in locoregionally advanced oropharyngeal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2013 |
Survival of patients with pathologic T0N+ oral and oropharyngeal cancer after neoadjuvant therapy and surgery: the minority report.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined C | 2013 |
Quality of life 2-10 years after combined treatment for advanced oral and oropharyngeal cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2002 |
[Radiation-induced mucositis and neutrophil granulocytes in oral mucosa].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Combined Modality Therapy | 2003 |
[Dynamic magnetic resonance tomography (dMRT). It's value in advanced head-neck tumors treated with radiochemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Contrast Media; Disease-Fr | 2003 |
[Metastatic oropharyngeal cancer successfully treated with docetaxel, cisplatin, 5-FU and l-leucovorin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel | 2004 |
Cyclin A as a predictive factor for chemotherapy response in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Cycle; C | 2004 |
Preoperative radiochemotherapy and radical resection for stages II-IV oral and oropharyngeal cancer: outcome of 222 patients.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2005 |
Preoperative radiochemotherapy and radical resection for stages II to IV oral and oropharyngeal cancer: grade of regression as crucial prognostic factor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Fe | 2005 |
Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; | 2006 |
[Pharmacokinetics and adverse event of TS-1 administered through gastrostomy].
Topics: Deglutition Disorders; Drug Administration Schedule; Drug Combinations; Fluorouracil; Gas Chromatogr | 2005 |
Survival impact of planned restaging and early surgical salvage following definitive chemoradiation for locally advanced squamous cell carcinomas of the oropharynx and hypopharynx.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; | 2005 |
Intensity-modulated radiation therapy in head and neck cancers: dosimetric advantages and update of clinical results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2005 |
Cancer in the oropharynx: cost calculation of different treatment modalities for controlled primaries, relapses and grade III/IV complications.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Cispl | 2005 |
[Angina pectoris and ST-elevation after chemotherapy with 5-fluorouracil].
Topics: Acute Coronary Syndrome; Aged; Angina Pectoris; Antineoplastic Combined Chemotherapy Protocols; Carc | 2007 |
Thymidine phosphorylase mRNA level predicts survival of patients with advanced oropharyngeal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Dihydrouracil Dehydrogenase | 2007 |
[The role of a surgical method in combined and complex treatment of patients with squamous cell oral and oropharyngeal cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2007 |
Influence of delayed tumor clearance on reliability of complete response rate in chemoradiotherapy for head and neck cancer.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Fluorouracil; | 2007 |
The aggravating factors of hyperammonemia related to 5-fluorouracil infusion--a report of two cases.
Topics: Brain Diseases; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorouracil; Humans; Hypera | 2008 |
[Treatment results of concurrent chemoradiotherapy with CDDP or CDGP plus 5-FU for carcinoma of the oropharynx and hypopharynx].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 2007 |
[Concurrent chemoradiotherapy for squamous cell carcinoma of the oropharynx].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2007 |
Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinom | 2008 |
Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinom | 2008 |
Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinom | 2008 |
Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinom | 2008 |
Chemotherapeutic management of head and neck malignancies with positron emission tomography.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxyglucose; F | 1995 |
Enhanced acute toxicity in oropharynx carcinoma treated with radiotherapy and concomitant cisplatin, 5-fluorouracil and mitomycin C.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1996 |
[Changes in the nuclear morphometry in oropharyngeal epidermoid carcinoma after induction chemotherapy].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; Humans; Immun | 1997 |
Quality of life of disease-free survivors of advanced (stage III or IV) oropharyngeal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 1997 |
Expression of platelet-derived endothelial cell growth factor in oral and oropharyngeal carcinoma.
Topics: Analysis of Variance; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Female; Fluorouraci | 1998 |
Brain infarction following 5-fluorouracil and cisplatin therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cerebral Infarction; Cisplatin; Fatal Outcome; | 1998 |
Concomitant boost radiotherapy in oropharynx carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 1998 |
Induction chemotherapy and radiation therapy for T4 oropharyngeal carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisp | 1999 |
Expression of hMSH2 correlates with in vitro chemosensitivity to CDDP cytotoxicity in oral and oropharyngeal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; DNA-Bind | 1998 |
[Alternating chemoradiotherapy for oropharyngeal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administrat | 2000 |
Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Erythropoietin; Female; Fl | 2001 |
Concomitant twice-a-day radiotherapy and chemotherapy in unresectable head and neck cancer patients: A long-term quality of life analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; En | 2001 |
[Medical cost analysis of neoadjuvant chemotherapy for advanced tongue and oropharyngeal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cost-Benefit Analysis; Female; Fluorour | 2001 |
[Vestibulotoxic effects of the cytostatic drug carboplatin in patients with head and neck tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Fluoroura | 1992 |
[Evaluating the effectiveness of chemotherapy in patients with head-neck tumors using positron emission tomography (PET scan)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Carcinoma; Carcinoma, Squamous Cell; | 1992 |
[Antineoplastic effectiveness and unwanted side effects of polychemotherapy of extensive oro- and hypopharyngeal cancers--results of a prospective therapy study with 5-FU/cisplatin versus 5-FU/carboplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Audiometry, Pure-Tone; Auditory Threshold; Bone Marr | 1992 |
Oropharynx carcinoma: irradiation alone versus induction chemotherapy plus irradiation--5 year results.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous C | 1990 |
[Simultaneous radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in advanced head and neck tumors].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 1991 |
Combined modality treatment of advanced cancers of the oral cavity and oropharynx.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Moda | 1991 |
[Incidence of osteoradionecrosis after combined radiotherapy-chemotherapy of head and neck tumors].
Topics: Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; | 1991 |
Optimization of preoperative chemotherapy by ultrasound. Follow-up in tumours of the oral cavity and oropharyngeal region.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Follow | 1990 |
[Induction chemotherapy in cancer of the upper respiratory and digestive tract. Preliminary results of the protocol combining cisplatin, 5-fluorouracil and bleomycin (CFB)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Comb | 1985 |
[Multidisciplinary treatment of head and neck cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin | 1985 |
Pretreatment with chemotherapy in patients with advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Cycl | 1985 |
Response to preoperative concomitant radiochemotherapy with mitomycin C and 5-fluorouracil in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Moda | 1989 |
[Preoperative radiochemotherapy in advanced oral and oropharyngeal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Moda | 1987 |